Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib

Current oncology

E.T. Masters¹  S. Iyer¹  K.L. Davis²  J.A. Kaye² 

[1] Pfizer, Inc.;RTI Health Solutions

关键词: Non-small cell;    lung cancer;    crizotinib;    outcome;   

DOI  :  10.3747/co.25.3723

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

BackgroundCrizotinib has shown greater efficacy in clinical trials than chemotherapy in patients with anaplastic lymphoma kinase-positive (alk+) non-small cell lung cancer (nsclc), but little information is available on its use and outcomes in real-world settings. We therefore assessed treatment patterns and outcomes in alk+ nsclc patients treated with crizotinib in regular clinical practice. MethodsA retrospective medical record review was conducted in North America for adults with alk+ nsclc treated with crizotinib as first- or later-line therapy for metastatic disease between 1 August 2011 and 31 March 2013 (for the United States) or 1 May 2012 and 31 March 2013 (for Canada). Crizotinib-related trial enrollees were excluded. Descriptive analyses were conducted to assess treatment patterns and objective response rate (orr). Progression-free survival (pfs) and overall survival (os) were descriptively analyzed using Kaplan-Meier methods. ResultsData were extracted for 212 patients in the United States ( n= 147) and Canada ( n= 65). Mean (standard deviation [sd]) age was 58.9 (9.5) years, and 69% were male. Seventy-nine patients (37%) were deceased at record abstraction. Sixty-five percent ( n= 137) initiated crizotinib as first-line therapy. Mean (sd) duration of crizotinib treatment was 8.7 (4.9) months. Objective response rate was 66% (69% for first-line recipients, 60% for second-/laterline). Median (95% ci) pfs and os from crizotinib initiation were 9.5 (8.7, 10.1) and 23.4 (19.5, ‒) months, respectively. One- and two-year survival probabilities were 82% and 49%, respectively. ConclusionsOutcomes for crizotinib recipients in this study align with previous trials, with orr appearing more favourable in first-line recipients. Our findings indicate that crizotinib outcomes in clinical studies may translate to regular clinical practice.

【 授权许可】

Unknown